Top

Published in:

01-04-2014 | IM - ORIGINAL

Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma

Authors: Amedeo Amedei, Fabio Munari, Chiara Della Bella, Elena Niccolai, Marisa Benagiano, Lapo Bencini, Fabio Cianchi, Marco Farsi, Giacomo Emmi, Giuseppe Zanotti, Marina de Bernard, Manikuntala Kundu, Mario Milco D’Elios

Published in: Internal and Emergency Medicine | Issue 3/2014

Abstract

Helicobacter pylori infection is characterized by an inflammatory infiltrate, consisting mainly of neutrophils and T cells. This study was undertaken to evaluate the type of gastric T cell response elicited by the secreted peptidyl prolyl cis, trans-isomerase of H. pylori (HP0175) in patients with distal gastric adenocarcinoma. The cytokine profile and the effector functions of gastric tumor-infiltrating lymphocytes (TILs) specific for HP0175 was investigated in 20 patients with distal gastric adenocarcinoma and H. pylori infection. The helper function of HP0175-specific TILs for monocyte MMP-2, MMP-9, and VEGF production was also investigated. TILs cells from H. pylori infected patients with distal gastric adenocarcinoma produced Interleukin (IL)-17 and IL-21 in response to HP0175. HP0175-specific TILs showed poor cytolytic activity while expressing helper activity for monocyte MMP-2, MMP-9 and VEGF production. These findings indicate that HP0175 is able to drive gastric Th17 response. Thus, HP0175, by promoting pro-inflammatory low cytotoxic TIL response, matrix degradation and pro-angiogenic pathways, may provide a link between H. pylori and gastric cancer.

Warren JR, Marshall BJ (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcer ulceration. Lancet 1:1311–1315PubMed

Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH et al (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325:1127–1131PubMedCrossRef

Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A et al (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575–577PubMedCrossRef

D’Elios MM, Appelmelk BJ, Amedei A, Bergman MP, Del Prete G (2004) Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 10:316–323PubMedCrossRef

Fox JG, Wang TC (2007) Inflammation, atrophy, and gastric cancer. J Clin Invest 117:60–69PubMedCentralPubMedCrossRef

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1994) Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61:1–241

D’Elios MM, Manghetti M, De Carli M, Costa F, Baldari CT et al (1997) Th1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 158:962–967PubMed

Kaparakis M, Philpott DJ, Ferrero RL (2007) Mammalian NLR proteins; discriminating foe from friend. Immunol Cell Biol 85:495–502PubMedCrossRef

Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A et al (2006) The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 116:1092–1101PubMedCentralPubMedCrossRef

10.

Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M et al (2000) Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 165:5332–5337PubMed

11.

Shi Y, Liu XF, Zhuang Y, Zhang JY, Liu T et al (2010) Helicobacter pylori-induced Th17 response modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J Immunol 184:5121–5129PubMedCrossRef

12.

Caruso R, Fina D, Peluso I, Fantini MC, Tosti C et al (2007) IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol 178:5957–5965PubMed

13.

Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P et al (2008) Critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses. Nat Immunol 9:650–657PubMedCrossRef

14.

Korn T, Bettelli E, Oukkaì M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517PubMedCrossRef

15.

Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N et al (1994) Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269:6271–6274PubMed

16.

Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25PubMedCrossRef

17.

Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18PubMedCrossRef

18.

Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361:888–898PubMedCrossRef

19.

Cone RE, Chattopadhyay S, Sharafieh R, Lemire Y, O’Rourke J et al (2009) T cell sensitivity to TGF-β is required for the effector function but not the generation of splenic CD8⁺ regulatory T cells induced via the injection of antigen into the anterior chamber. Int Immunol 21:567–574PubMedCentralPubMedCrossRef

20.

Sebkova L, Pellicanò A, Monteleone G, Grazioli B, Guarnieri G et al (2004) Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells. Infect Immun 72:5019–5026PubMedCentralPubMedCrossRef

21.

Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9–34PubMedCrossRef

22.

Zhang B, Rong G, Wei H, Zhang M, Bi J et al (2008) The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374:533–537PubMedCrossRef

23.

Codolo G, Amedei A, Steere AC, Papinutto E, Cappon A et al (2008) Borrelia burgdorferi-NapA driven Th17 cell inflammation in Lyme arthritis. Arthritis Rheum 58:3609–3617PubMedCrossRef

24.

Pathak SK, Basu S, Bhattacharyya A, Pathak S, Banerjee A et al (2006) TLR4-dependent NF-kappaB activation and mitogen- and stress-activated protein kinase 1-triggered phosphorylation events are central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase (HP0175)-mediated induction of IL-6 release from macrophages. J Immunol 177:7950–7958PubMed

25.

Basu S, Pathak SK, Chatterjee G, Pathak S, Basu J et al (2008) Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells. J Biol Chem 283:32369–32376PubMedCrossRef

26.

Basak C, Pathak SK, Bhattacharyya A, Pathak S, Basu J et al (2005) The secreted peptidyl prolyl cis, trans-isomerase HP0175 of Helicobacter pylori induces apoptosis of gastric epithelial cells in a TLR4- and apoptosis signal-regulating kinase 1-dependent manner. J Immunol 174:5672–5680PubMed

27.

Amedei A, Niccolai E, Della Bella C, Cianchi F, Trallori G et al (2009) Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. Cancer Immunol Immunother 58:1819–1830PubMedCrossRef

28.

D’Elios MM, Bergman MP, Azzurri A, Amedei A, Benagiano M et al (2001) H(+), K(+)-ATPase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology 120:377–386PubMedCrossRef

29.

D’Elios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G (2005) Helicobacter pylori, T cells and cytokines: the “dangerous liaisons”. FEMS Immunol Med Microbiol 44:113–119PubMedCrossRef

30.

Fox JG, Beck P, Dangler CA, Whary MT, Wang TC et al (2000) Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 6:536–542PubMedCrossRef

31.

D’Elios MM, Manghetti M, Almerigogna F, Amedei A, Costa F et al (1997) Different cytokine profile and antigen-specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol 27:1751–1755PubMedCrossRef

32.

El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402PubMedCrossRef

33.

El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH et al (2001) The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 412:99–103PubMedCrossRef

34.

Caruso R, Fina D, Paoluz OA, Del Vecchio Blanco G, Stolfi C et al (2008) IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol 38:470–478PubMedCrossRef

35.

Zhang JY, Liu T, Guo H, Liu XF, Zhuang Y et al (2011) Induction of a Th17 cell response by Helicobacter pylori urease subunit B. J Immunol 216:803–810

36.

D’Elios MM, Andersen LP (2009) Inflammation, immunity, and vaccines for H. pylori. Helicobacter 14(S1):21–28

37.

Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016–1022PubMedCentralPubMedCrossRef

38.

Langowski JL, Zhang X, Wu L, Mattson JD, Chen T et al (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465PubMedCrossRef

39.

Meulmeester E, Ten Dijke P (2011) The dynamic roles of TGF-β in cancer. J Pathol 223:205–218PubMedCrossRef

40.

Tuccillo C, Cuomo A, Rocco A, Martinelli E, Staibano S et al (2005) Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. J Pathol 207:277–284PubMedCrossRef

Title: Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma
Authors: Amedeo Amedei
Fabio Munari
Chiara Della Bella
Elena Niccolai
Marisa Benagiano
Lapo Bencini
Fabio Cianchi
Marco Farsi
Giacomo Emmi
Giuseppe Zanotti
Marina de Bernard
Manikuntala Kundu
Mario Milco D’Elios
Publication date: 01-04-2014
Publisher: Springer Milan
Published in: Internal and Emergency Medicine / Issue 3/2014
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-012-0867-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Behçet’s syndrome pathophysiology and potential therapeutic targets

Effects of smoking in patients treated with cardiac resynchronization therapy

Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies

Balloon valvuloplasty for treatment of cardiogenic shock in the era of surgical valve replacement and TAVI

Reversible posterior leukoencephalopathy syndrome

3′-UTR OLR1/LOX-1 gene polymorphism and endothelial dysfunction: molecular and vascular data in never-treated hypertensive patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials